Background: Treatment of non-malignant portal vein thrombosis (PVT) in patients with cirrhosis has been neglected in the past because of the fear of bleeding complications when using anticoagulation and due to the technical difficulties associated with the implantation of the transjugular intrahepatic portosystemic shunt (TIPS). However, PVT has a negative impact on outcome and compromises liver transplantation, warranting treatment by using anticoagulation and TIPS. Methods: This review considers studies on the treatment of PVT in cirrhosis published in the last 10 years. Unfortunately, many of these studies are limited by their retrospective design and a small sample size. Results: Anticoagulation using low-molecular-weight heparin (LMWH) or vitamin K antagonists is effective in the treatment of patients with limited and recent PVT, resulting in a recanalization in up to 50% of the patients. TIPS (plus local measures) results in a recanalization of up to 100% and reduces the rebleeding rate considerably in patients with recent or chronic PVT. Conclusion: Based on the presently limited knowledge, a therapy algorithm is suggested favouring the TIPS as a first-line treatment for PVT in patients with symptomatic portal hypertension. Patients with thus far asymptomatic portal hypertension may first receive anticoagulation, preferably using LMWH. If these patients have a condition where anticoagulation is not promising (complete, extended, chronic PVT) or ineffective, or if they are candidates for liver transplantation, the TIPS may be implanted without delay.

Journal Section:
Editor's choice
Keywords:
Portal vein thrombosis, Cirrhosis, Therapy, Algorithm, Anticoagulation, Transjugular shunt
1.
Maruyama H, Okugawa H, Takahashi M, Yokosuka O: De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol 2013;108:568-574.
2.
Werner KT, Sando S, Carey EJ, et al: Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013;58:1776-1780.
3.
Chen H, Qi X, He C, Yin Z, Fan D, Han G: Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis. Thromb Res 2013;131:173-177.
4.
Delgado MG, Seijo S, Yepes I, et al: Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-783.
5.
Kinjo N, Kawanaka H, Akahoshi T, et al: Portal vein thrombosis in liver cirrhosis. World J Hepatol 2014;6:64-71.
6.
Francoz C, Belghiti J, Vilgrain V, et al: Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.
7.
Amitrano L, Guardascione MA, Menchise A, et al: Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenetrol 2010;44:448-451.
8.
Senzolo M, Sartori T, Rosetto V, et al: Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919-927.
9.
Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P: Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011;31:75-82.
10.
Rodriguez-Castro KI, Senzolo M: Optimal length of anticoagulation therapy in cirrhotic patients with portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:820-821.
11.
Rössle M, Haag K, Ochs A, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-171.
12.
Rössle M: TIPS: 25 years later. J Hepatol 2013;59:1081-1093.
13.
Lautt WW: Regulatory processes interacting to maintain hepatic blood flow constancy: vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res 2007;37:891-893.
14.
Hassoun Z, Deschenes M, Lafortune M, et al: Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. Am J Gastroenterol 2001;96:1205-1209.
15.
Deng D, Liao MS, Qin JP, Li XA: Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int 2006;5:232-236.
16.
D'Avola D, Bilbao JI, Zozaya G, et al: Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. Transplant Proc 2012;44:2603-2605.
17.
Luca A, Miraglia R, Caruso S, et al: Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011;60:846-852.
18.
Senzolo M, Tibbals J, Cholongitas E, et al: Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006;23:767-775.
19.
Perarnau JM, Baju A, D'alteroche L, et al: Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol 2010;22:1093-1098.
20.
Han G, Qi X, He C, et al: Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011;54:78-88.
21.
Bauer J, Johnson S, Durham J, et al: The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl 2006;12:1544-1551.
22.
Liatsos C, Vlachogiannakos J, Patch D, et al: Successful recanalization of portal vein thrombosis before liver transplantation using transjugular intrahepatic portosystemic shunt. Liver Transpl 2001;7:453-460.
23.
Fanelli F, Angeloni S, Salvatori FM, et al: Transjugular intrahepatic portosystemic shunt with expanded-polytetrafluorethylene-covered stents in non-cirrhotic patient with portal cavernoma. Dig Liver Dis 2011;43:78-84.
24.
Qi X, Han G, Yin Z, et al: Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci 2012;57:1072-1082.
25.
Siegerstetter V, Huber M, Ochs A, Blum HE, Rössle M: Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidin with heparin treatment. Hepatology 1999;29:33-38.
26.
Garcia-Pagan JC, Caca K, Bureau C, et al: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;162:2370-2379.
27.
Salerno F, Camma C, Enea A, et al: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825-834.
28.
Rössle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-1707.
29.
Qi X, Han G, Fan D: Degree of portal vein thrombosis might be associated with recanalization during anticoagulation. Clin Gastroenterol Hepatol 2012;10:820.
30.
Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion DM: Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010;16:999-1005.
31.
Lendoire J, Raffin G, Cejas N, et al: Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford) 2007;9:352-356.
32.
Egawa H, Tanaka K, Kasahara M, et al: Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl 2006;12:1512-1518.
33.
Doenecke A, Tsui T-Y, Zuelke C, et al: Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity. Clin Transplant 2010;24:48-55.
34.
Freeman RB, FitzMaurice SE, Greenfield AE, Halin N, Haug CE, Rohrer RJ: Is the transjugular intrahepatic portosystemic shunt procedure beneficial for liver transplant recipients? Transplantation 1994;15:297-300.
35.
Millis JM, Martin P, Gommes A, et al: Transjugular intrahepatic portosystemic shunts: impact on liver transplantation. Liver Transpl Surg 1995;1:229-233.
36.
Chiu AKK, Rao ARN, Waugh RC, et al: Liver transplantation in patients with transjugular intrahepatic portosystemic shunts. Aust N Z J Surg 2000;70:493-495.
37.
Tripathi D, Therapondos G, Redhead DN, Madhavan KK, Hayes PC: Transjugular intrahepatic portosystemic stent-shunt and its effects on orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2002;14:827-832.
38.
Guerrini GP, Pleguezuelo M, Maimone S, et al: Impact of TIPS preliver transplantation for the outcome posttransplantation. Am J Transplant 2009;9:192-200.
39.
Barbier L, Hardwigsen J, Borentain P, et al: Impact of transjugular intrahepatic portosystemic shunting on liver transplantation: 12-year single-center experience. Clin Res Hepatol Gastroenterol 2014;38:155-163.
40.
Amitrano L, Guardascione MA, Brancaccio V, et al: Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736-741.
41.
Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK: Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31:366-374.
42.
Rössle M, Gerbes AL: TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010;59:988-1000.
43.
Villa E, Camma C, Marietta M, et al: Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253-1260.
44.
Luca A, Caruso S, Milazzo M, et al: Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology 2012;265:124-132.
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.